Welcome, Guest. Please login or register.
December 15, 2019, 09:05:33 pm

Login with username, password and session length

 

Members
Stats
  • Total Posts: 249
  • Total Topics: 119
  • Online Today: 61
  • Online Ever: 139
  • (October 31, 2018, 04:13:53 am)
Users Online
Users: 0
Guests: 4
Total: 4

Welcome!

Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Opdivo Plus Yervoy Shows Promise for Advanced Liver Cancer  (Read 78 times)

Offline Cancer Health Editors

  • Newbie
  • *
  • Posts: 49
    • View Profile
Opdivo Plus Yervoy Shows Promise for Advanced Liver Cancer
« on: December 04, 2019, 01:08:18 pm »
Combining two different types of checkpoint inhibitor immunotherapy led to improved outcomes in people with advanced liver cancer, according to study results presented this week at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

People treated with the most effective regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) had an overall response rate of 32% and a median survival of nearly two years—better than the outcomes seen with Opdivo alone. The dual treatment was generally safe and side effects were described as manageable.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes can lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC is often detected late and is difficult to treat, as it generally does not respond well to traditional chemotherapy. Opdivo and a similar immunotherapy, Keytruda (pembrolizumab), as well as several targeted therapies, have been approved for HCC treatment in recent years.

Read more...
https://www.cancerhealth.com/article/opdivo-plus-yervoy-shows-promise-advanced-liver-cancer

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.